Biology:Cathepsin

From HandWiki
Short description: Family of proteases
Cathepsin
Cathepsin K 1TU6.png
Structure of Cathepsin K
Identifiers
SymbolCTP
PfamPF00112
Pfam clanCL0125
InterProIPR000668
SMARTPept_C1
PROSITEPDOC00126
MEROPSC1
SCOP21aec / SCOPe / SUPFAM

Cathepsins (Ancient Greek kata- "down" and hepsein "boil"; abbreviated CTS) are proteases (enzymes that degrade proteins) found in all animals as well as other organisms. There are approximately a dozen members of this family, which are distinguished by their structure, catalytic mechanism, and which proteins they cleave[citation needed]. Most of the members become activated at the low pH found in lysosomes. Thus, the activity of this family lies almost entirely within those organelles. There are, however, exceptions such as cathepsin K, which works extracellularly after secretion by osteoclasts in bone resorption. Cathepsins have a vital role in mammalian cellular turnover.

Classification


Clinical significance

Cathepsins are involved in many physiological processes have been implicated in a number of human diseases. The cysteine cathepsins have attracted significant research effort as drug targets.[1][2]

Cathepsin A

Deficiencies in this protein are linked to multiple forms of galactosialidosis. The cathepsin A activity in lysates of metastatic lesions of malignant melanoma is significantly higher than in primary focus lysates. Cathepsin A increased in muscles moderately affected by muscular dystrophy and denervating diseases.

Cathepsin B

Cathepsin B may function as a beta-secretase 1, cleaving amyloid precursor protein to produce amyloid beta.[10] Overexpression of the encoded protein, which is a member of the peptidase C1 family, has been associated with esophageal adenocarcinoma and other tumors.[11] Cathepsin B has also been implicated in the progression of various human tumors[3] including ovarian cancer.

Cathepsin D

Cathepsin D (an aspartyl protease) appears to cleave a variety of substrates such as fibronectin and laminin. Unlike some of the other cathepsins, cathepsin D has some protease activity at neutral pH.[12] High levels of this enzyme in tumor cells seems to be associated with greater invasiveness.

Cathepsin K

Cathepsin K is the most potent mammalian collagenase. Cathepsin K is involved in osteoporosis, a disease in which a decrease in bone density causes an increased risk for fracture. Osteoclasts are the bone resorbing cells of the body, and they secrete cathepsin K in order to break down collagen, the major component of the non-mineral protein matrix of the bone.[13] Cathepsin K, among other cathepsins, plays a role in cancer metastasis through the degradation of the extracellular matrix.[14] The genetic knockout for cathepsin S and K in mice with atherosclerosis was shown to reduce the size of atherosclerotic lesions.[15] The expression of cathepsin K in cultured endothelial cells is regulated by shear stress.[16] Cathepsin K has also been shown to play a role in arthritis.[17]

Cathepsin V

Mouse cathepsin L is homologous to human cathepsin V.[18] Mouse cathepsin L has been shown to play a role in adipogenesis and glucose intolerance in mice. Cathepsin L degrades fibronectin, insulin receptor (IR), and insulin-like growth factor 1 receptor (IGF-1R). Cathepsin L-deficient mice were shown to have less adipose tissue, lower serum glucose and insulin levels, more insulin receptor subunits, more glucose transporter (GLUT4) and more fibronectin than wild type controls.[19]

Inhibitors

Five cyclic peptides show inhibitory activity towards human cathepsins L, B, H, and K.[20] Several inhibitors have reached clinical trials, targeting cathepsins K and S as promising therapeutics for osteoporosis, osteoarthritis, and chronic pain. Cathepsin K inhibitors, Relacatib, Balicatib, and Odanacatib, were terminated during clinical trials at phases I, II, and III, respectively, owing to adverse side effects.[21] SAR114137, a Cathepsin S inhibitor, did not progress past phase I for chronic pain. In 2022, STI-1558, a Cathepsin L inhibitor, received FDA clearance to begin phase I studies to treat COVID-19.[22]

Cathepsin zymography

Zymography is a type of gel electrophoresis that uses a polyacrylamide gel co-polymerized with a substrate in order to detect enzyme activity. Cathepsin zymography separates different cathepsins based on their migration through a polyacrylamide gel co-polymerized with a gelatin substrate. The electrophoresis takes place in non-reducing conditions, and the enzymes are protected from denaturation using leupeptin.[23] After protein concentration is determined, equal amounts of tissue protein are loaded into a gel. The protein is then allowed to migrate through the gel. After electrophoresis, the gel is put into a renaturing buffer in order to return the cathepsins to their native conformation. The gel is then put into an activation buffer of a specific pH and left to incubate overnight at 37 °C. This activation step allows the cathepsins to degrade the gelatin substrate. When the gel is stained using a Coomassie blue stain, areas of the gel still containing gelatin appear blue. The areas of the gel where cathepsins were active appear as white bands. This cathepsin zymography protocol has been used to detect femtomole quantities of mature cathepsin K.[23] The different cathepsins can be identified based on their migration distance due to their molecular weights: cathepsin K (~37 kDa), V (~35 kDa), S (~25kDa), and L (~20 kDa). Cathepsins have specific pH levels at which they have optimum proteolytic activity. Cathepsin K is able to degrade gelatin at pH 7 and 8, but these pH levels do not allow for cathepsins L and V activity. At a pH 4 cathepsin V is active, but cathepsin K is not. Adjusting the pH of the activation buffer can allow for further identification of cathepsin types.[24]

History

The term cathepsin was coined in 1929 by Richard Willstätter and Eugen Bamann to describe a proteolytic activity of leukocytes and tissues at slightly acidic pH (Willstätter & Bamann (1929) Hoppe-Seylers Z. Physiol. Chemie 180, 127-143). The earliest record of "cathepsin" found in the MEDLINE database (e.g., via PubMed) is from the Journal of Biological Chemistry in 1949.[25] However, references within this article indicate that cathepsins were first identified and named around the turn of the 20th century. Much of this earlier work was done in the laboratory of Max Bergmann, who spent the first several decades of the century defining these proteases.[26]

It is notable that research published in the 1930s (primarily by Bergmann) used the term "catheptic enzymes" to refer to a broad family of proteases that included papain, bromelin, and cathepsin itself.[27] Initial efforts to purify and characterize proteases using hemoglobin transpired at a time when the word "cathepsin" indicated a single enzyme;[28] the existence of multiple, distinct cathepsin family members (e.g. B, H, L) did not appear to be understood at the time. However, by 1937 Bergmann and colleagues began to differentiate cathepsins on the basis of their source in the human body (e.g. liver cathepsin, spleen cathepsin).[26]

References

  1. ↑ Novinec, Marko; Lenarčič, Brigita (1 June 2013). "Papain-like peptidases: structure, function, and evolution". BioMolecular Concepts 4 (3): 287–308. doi:10.1515/bmc-2012-0054. PMID 25436581. 
  2. ↑ Turk, Vito; Stoka, Veronika; Vasiljeva, Olga; Renko, Miha; Sun, Tao; Turk, Boris; Turk, Dušan (January 2012). "Cysteine cathepsins: From structure, function and regulation to new frontiers". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1824 (1): 68–88. doi:10.1016/j.bbapap.2011.10.002. PMID 22024571. 
  3. ↑ 3.0 3.1 "Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells". J. Med. Invest. 52 (1–2): 1–9. February 2005. doi:10.2152/jmi.52.1. PMID 15751268. http://medical.med.tokushima-u.ac.jp/jmi/vol52/pdf/v52_n1-2_p001.pdf. 
  4. ↑ Lipton P (October 1999). "Ischemic cell death in brain neurons". Physiol. Rev. 79 (4): 1431–568. doi:10.1152/physrev.1999.79.4.1431. PMID 10508238. 
  5. ↑ "Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice". Mediators of Inflammation 2013 (2013): 187873. Oct 24, 2013. doi:10.1155/2013/187873. PMID 24282339. 
  6. ↑ Yamashima T (2013). "Reconsider Alzheimer's disease by the 'calpain-cathepsin hypothesis'--a perspective review". Progress in Neurology 105: 1–23. doi:10.1016/j.pneurobio.2013.02.004. PMID 23499711. https://zenodo.org/record/895448. 
  7. ↑ "Serine protease cathepsin G regulates adhesion-dependent neutrophil effector functions by modulating integrin clustering". Immunity 22 (6): 679–91. June 2005. doi:10.1016/j.immuni.2005.03.015. PMID 15963783. 
  8. ↑ Chandran K (2005). "Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection". Science 308 (5728): 1643–1645. doi:10.1126/science.1110656. PMID 15831716. Bibcode: 2005Sci...308.1643C. 
  9. ↑ "The role of cathepsins in ocular physiology and pathology". Exp. Eye Res. 84 (3): 383–8. March 2007. doi:10.1016/j.exer.2006.05.017. PMID 16893541. 
  10. ↑ Hook, Gregory; Hook, Vivian; Kindy, Mark (2011-01-01). "The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity". Journal of Alzheimer's Disease 26 (2): 387–408. doi:10.3233/JAD-2011-110101. ISSN 1875-8908. PMID 21613740. 
  11. ↑ Habibollahi, Peiman; Figueiredo, Jose-Luiz; Heidari, Pedram; Dulak, Austin M; Imamura, Yu; Bass, Adam J.; Ogino, Shuji; Chan, Andrew T et al. (2012). "Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy". Theranostics 2 (2): 227–234. doi:10.7150/thno.4088. PMID 22400064. 
  12. ↑ "Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions". Journal of Cell Science 117 (Pt 21): 5155–5164. 2004. doi:10.1242/jcs.01396. PMID 15456852. 
  13. ↑ "Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2". FEBS Lett. 357 (2): 129–34. January 1995. doi:10.1016/0014-5793(94)01349-6. PMID 7805878. https://deepblue.lib.umich.edu/bitstream/2027.42/116965/1/feb20014579394013496.pdf. 
  14. ↑ "Cysteine cathepsins and the cutting edge of cancer invasion". Cell Cycle 6 (1): 60–4. January 2007. doi:10.4161/cc.6.1.3669. PMID 17245112. 
  15. ↑ "Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation". Circulation 113 (1): 98–107. January 2006. doi:10.1161/CIRCULATIONAHA.105.561449. PMID 16365196. 
  16. ↑ "Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis". Am. J. Physiol. Heart Circ. Physiol. 292 (3): H1479–86. March 2007. doi:10.1152/ajpheart.00954.2006. PMID 17098827. 
  17. ↑ "Role of cathepsin K in normal joints and in the development of arthritis". Curr Drug Targets 8 (2): 315–23. February 2007. doi:10.2174/138945007779940188. PMID 17305509. 
  18. ↑ "Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization". Biochemistry 38 (8): 2377–85. February 1999. doi:10.1021/bi982175f. PMID 10029531. 
  19. ↑ "Cathepsin L activity controls adipogenesis and glucose tolerance". Nat. Cell Biol. 9 (8): 970–7. August 2007. doi:10.1038/ncb1623. PMID 17643114. 
  20. ↑ "Affinity selection to papain yields potent peptide inhibitors of cathepsins L, B, H, and K.". Biochemical and Biophysical Research Communications 332 (3): 897–903. 2005. doi:10.1016/j.bbrc.2005.05.028. PMID 15913550. 
  21. ↑ Mullard, Asher (2016-10-01). "Merck & Co. drops osteoporosis drug odanacatib" (in en). Nature Reviews Drug Discovery 15 (10): 669. doi:10.1038/nrd.2016.207. ISSN 1474-1784. PMID 27681784. 
  22. ↑ Cooley, Brian (July 19, 2022). ""Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19"". Sorrento Therapeutics, Inc.. https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-fda-ind-clearance-sti-1558-oral#:~:text=News%20Release-,Sorrento%20Therapeutics%20Announces%20the%20FDA%20IND%20Clearance%20of%20STI%2D1558,Inhibitor%20to%20Treat%20COVID%2D19&text=STI%2D1558%2C%20an%20oral%20SARS,standalone%20treatment%20of%20COVID%2D19.. 
  23. ↑ 23.0 23.1 "Detection of femtomole quantities of mature cathepsin K with zymography". Anal. Biochem. 401 (1): 91–8. June 2010. doi:10.1016/j.ab.2010.02.035. PMID 20206119. 
  24. ↑ "Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues". Arch. Biochem. Biophys. 516 (1): 52–7. December 2011. doi:10.1016/j.abb.2011.09.009. PMID 21982919. 
  25. ↑ "The hydrolysis of nucleoproteins by cathepsins from calf thymus". J. Biol. Chem. 181 (2): 853–60. December 1949. doi:10.1016/S0021-9258(18)56608-4. PMID 15393803. 
  26. ↑ 26.0 26.1 "Regarding the general nature of catheptic enzymes". Science 84 (2169): 89–90. July 1936. doi:10.1126/science.84.2169.89. PMID 17748131. Bibcode: 1936Sci....84...89B. 
  27. ↑ "On proteolytic enzymes XV. Regarding the general nature of intracellular proteolytic enzymes". The Journal of Biological Chemistry 119: 35–46. June 1, 1937. doi:10.1016/S0021-9258(18)74429-3. 
  28. ↑ Anson, M. L. (September 1936). "The estimation of cathepsin with hemoglobin and the partial purification of cathepsin". The Journal of General Physiology 20 (4): 565–574. doi:10.1085/jgp.20.4.565. PMID 19873011. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Cathepsin&oldid=3564531"